Edaravone oral

Drug Profile

Edaravone oral

Alternative Names: TW001

Latest Information Update: 14 Dec 2015

Price : $50

At a glance

  • Originator Treeway
  • Class Neuroprotectants; Pyrazolones; Small molecules
  • Mechanism of Action Antioxidants; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Amyotrophic lateral sclerosis

Most Recent Events

  • 10 Dec 2015 Treeway plans a phase II/III trial for Amyotrophic lateral sclerosis
  • 12 Mar 2015 Edaravone oral receives Orphan Drug status for Amyotrophic lateral sclerosis in USA
  • 01 Dec 2014 Edaravone oral receives Orphan Drug status for Amyotrophic lateral sclerosis in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top